Hutchison China MediTech Limited ("Chi-Med") is a China-based globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products.

Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is listed on the London Stock Exchange’s AIM market (AIM: HCM). It is majority owned by CK Hutchison Holdings Limited (SEHK: 0001), a leading international conglomerate committed to innovation and technology with over a quarter of a million employees in more than 50 countries and annual sales of over US$50 billion.

http://www.chi-med.com/eng/global/home.php

Hutchison China Meditech: Panmure Gordon raises target price from 1200p to 1500p and keeps a 'buy' recommendation.

Director's Shareholding

RNS


RNS Number : 5784X

Hutchison China Meditech Limited

20 November 2014












Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Director's Shareholding





London: Thursday, 20 November 2014: Chi-Med received notification on 20 November 2014 that Mr Simon To, Executive Chairman and Director of Chi-Med, purchased 41,000 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of GBP13.50 per share on 18 November 2014.



Following this purchase, Mr To is beneficially interested in 41,000 Shares, representing approximately 0.08% of the current issued share capital of Chi-Med.

Hutchison China MediTech: UBS raises target price from 1200p to 1590p and reiterates a 'buy' recommendation.

Initiation of fruquintinib Phase III study

RNS


RNS Number : 7343Z

Hutchison China Meditech Limited

15 December 2014






Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)



Initiation of fruquintinib Phase III registration study in colorectal cancer



London: Monday, 15 December 2014: Chi-Med today announces that Hutchison MediPharma Limited ("HMP"), its majority owned R&D company, has initiated FRESCO, a Phase III registration study in colorectal cancer ("CRC") patients in China, for fruquintinib (HMPL-013), its investigational small molecule which selectively inhibits vascular endothelial growth factor receptors ("VEGFR"). Preparations and site selection began in the middle of this year, with the first patient dosed on 12 December 2014.



This randomised, double-blind, placebo-controlled, multicentre, Phase III registration study is targeted at treating patients with locally advanced or metastatic CRC, who have failed at least two prior systemic antineoplastic therapies, including fluoropyrimidine, oxaliplatin and irinotecan. Patients will be randomised at a 2:1 ratio to receive either: 5 milligrams of fruquintinib orally once per day, on a three-weeks-on / one-week-off cycle, plus best supportive care ("BSC"); or placebo plus BSC. The primary endpoint is overall survival, with secondary endpoints including progression free survival, objective response rate, disease control rate and duration of response. More than 400 patients will be enrolled in about 25 centres, with top-line results expected in 2016.



Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3. In the first-in-human Phase I clinical trial 40 patients were treated with fruquintinib. Detailed results of the Phase I clinical trial are available at http://chi-med.com/eng/irinfo/presentations.htm, and were presented at the annual meeting of the American Association for Cancer Research in April 2013. Based on the Phase I data in CRC, a Phase Ib study was initiated which treated a further 62 CRC patients. Detailed results of the Phase Ib clinical trial were presented at the annual meeting of the American Society of Clinical Oncology in May 2014, and also can be found at http://chi-med.com/eng/irinfo/presentations.htm. Clinical trials for solid tumours including CRC, non-small cell lung cancer and gastric cancer are ongoing at various stages in China as either single-agent therapy or combined with chemotherapy.



In October 2013, HMP entered into a licensing, co-development and commercialisation agreement in China with Eli Lilly and Company for fruquintinib.



Ends
---------------------------------------------------------------------------------------------
15 Dec Panmure Gordon 1,500.00 Buy

Notice of Results
RNS
RNS Number : 9946C
Hutchison China Meditech Limited
26 January 2015









Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Notice of Announcement of 2014 Final Results





London: Monday, 26 January 2015: Chi-Med will be announcing its final results for the year ended 31 December 2014 on Thursday, 26 February 2015. An analyst presentation will be held at 9:00 am on the same day at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY.

Distribution Agreement for Seroquel in China
RNS
RNS Number : 4649D
Hutchison China Meditech Limited
29 January 2015







Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)



Press Release

Hutchison Sinopharm and AstraZeneca China

signed an exclusive distribution agreement on Seroquel® in China



London: Thursday, 29 January 2015: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces thatHutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"), a subsidiary of Chi-Med, has entered intoan exclusive distributionagreement with AstraZeneca (Wuxi) Trading Co., Ltd. ("AstraZeneca"), a subsidiary of AstraZeneca PLC, to distribute and market in China the product Seroquel®, an antipsychotic prescription drug owned by AstraZeneca PLC.



Hutchison Sinopharm will be the exclusive first-tier distributor todistribute and marketAstraZeneca's Quetiapine Tablets, under the Seroquel® trademarkin China. Seroquel® is a first-line antipsychotic medicine for the treatment of schizophrenia and bipolar disorder, which was launched in China in 2001. The compound annual growth rate of the antipsychotic prescription drug market in China was approximately 21%from 2009 to 2013 driven by increasing awareness, diagnosis and treatment of central nervous system related diseases in China.



Hutchison Sinopharm, established in April 2014, provides marketing and commercialisation services to pharmaceutical companies in China. Chi-Med, through Hutchison Sinopharm as well as Shanghai Hutchison Pharmaceuticals Limited, currently operates a commercial network in China of over 1,600 medical sales representatives covering more than 13,000 hospitals.



Christian Hogg, Chi-Med CEO said: "This exciting collaboration with AstraZeneca, a most important strategic partner for Chi-Med, will allow us to leverage our considerable commercial presence in China against a highly attractive and fast growing commercial opportunity. Seroquel® is a very strong global brand and we look forward to helping to grow its distribution and business in China."





Ends

29 Jan Panmure Gordon 1,600.00 Buy

Final Results


Consolidated Group Results (IFRS11)

· Revenue up 100% to $91.8 million (2013: $46.0m).

· Net profit attributable to Chi-Med equity holders of $5.4 million (2013: $5.9m) as the Company continues to balance a dramatic increase in clinical trial activity on seven new drug candidates with rapidly increasing profit in the China Healthcare Division.

· Cash positive overall during 2014 with Group level cash and bank balances of $51.1 million (31 December 2013: $46.9m). In addition, cash and bank balances held at the joint venture ("JV") level $77.0 million (31 December 2013: $99.0m) which is being used to fund construction of two new large-scale factories.

26 Feb Panmure Gordon 1,600.00 Buy

Patient enrolment completion for Phase II study
RNS
RNS Number : 7433G
Hutchison China Meditech Limited
06 March 2015







Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Patient enrolment completion for fruquintinib's Phase II study in non-small cell lung cancer. Fruquintinib development moving rapidly in four parallel studies in non-small cell lung cancer, colorectal cancer and gastric cancer.



London: Friday, 6 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in non-small cell lung cancer ("NSCLC") patients in China. The proof-of-concept ("POC") study is investigating the efficacy and safety of fruquintinib, HMP's investigational small molecule inhibitor of vascular endothelial growth factor receptors ("VEGFR").



This randomised, double-blind, placebo-controlled, multi-centre, POC Phase II study is targeted at treating non-squamous NSCLC patients who have failed second-line standard chemotherapy. A total of 91 patients have now been randomised to receive fruquintinib plus best supportive care ("BSC") or placebo plus BSC at a 2:1 ratio. The primary endpoint is progression free survival, with secondary endpoints including disease control rate, overall response rate, overall survival and safety. As a result of the rapid patient enrolment, data from this trial is expected in mid of 2015.



Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3. In the first-in-human Phase I clinical trial 40 patients were treated with fruquintinib. Detailed results of the Phase I clinical trial are available at http://chi-med.com/eng/irinfo/presentations.htm, and were presented at the annual meeting of the American Association for Cancer Research in April 2013.



Based on the Phase I data in colorectal cancer ("CRC"), a Phase Ib study was initiated which treated a further 62 CRC patients. Detailed results of the Phase Ib clinical trial were presented at the annual meeting of the American Society of Clinical Oncology in May 2014, and also can be found at http://chi-med.com/eng/irinfo/presentations.htm.



In April 2014, HMP initiated the first POC Phase II study, which was a randomised, double-blind, placebo-controlled, multi-centre Phase II clinical trial targeted at patients with metastatic CRC. The POC Phase II study subsequently completed enrolment in August 2014, and will report data during the first half of 2015.



In October 2014, HMP initiated a Phase Ib dose-finding study of fruquintinib, in combination with paclitaxel, in second line gastric cancer patients.



In December 2014, HMP initiated FRESCO, a Phase III registration study in patients with locally advanced or metastatic CRC, who have failed at least two prior systemic antineoplastic therapies, including flouropyrimidine, oxaliplatin and irinotecan. FRESCO will enrol more than 400 patients in 25 centres in China, with top-line results expected in 2016.



In October 2013, HMP entered into a licensing, co-development and commercialisation agreement in China with Eli Lilly and Company for fruquintinib.





Ends

Trial of fruquintinib achieves primary endpoint
RNS
RNS Number : 7809I
Hutchison China Meditech Limited
30 March 2015







Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





The first proof-of-concept trial of fruquintinib achieves primary efficacy endpoint



London: Monday, 30 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, successfully achieved the primary endpoint in the first proof-of-concept ("POC") trial of fruquintinib in patients with metastatic colorectal cancer ("mCRC") in China. The top-line results demonstrated that the trial clearly succeeded in meeting the primary efficacy endpoint of progression free survival.



Assessment of secondary efficacy endpoints, including objective response rate, disease control rate, and overall survival is ongoing, with all appearing in-line with expectations at the February 2015 six-month data cut-off. The adverse events demonstrated in this POC study are consistent with the known safety profile for fruquintinib without major unexpected safety issues. Full detailed results from this trial will be disclosed in due course.



This is the first POC Phase II study for fruquintinib aimed at comparing the efficacy and safety of fruquintinib plus best supportive care ("BSC") versus placebo plus BSC in patients with mCRC as a third-line or above therapy. It is a randomised, double-blind, placebo-controlled, multi-centre, POC Phase II study to treat mCRC patients who have failed at least two prior chemotherapies, including fluoropyrimidine, oxaliplatin and irinotecan. A total of 71 patients were randomised to receive fruquintinib plus BSC or placebo plus BSC at a 2:1 ratio. The trial was initiated in April 2014 and completed patient enrolment in August 2014.



30 Mar Panmure Gordon 1,650.00 Buy

Director purchases

Today 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 01 02 03 04 05 06 07 08 09 10 11 12 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Time: (hh:mm) RNS: MonAM:
To: Today 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 01 02 03 04 05 06 07 08 09 10 11 12 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Time: (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above



Director's Shareholding
RNS
RNS Number : 9717J
Hutchison China Meditech Limited
13 April 2015







Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Director's Shareholding





London: Monday, 13 April 2015: Chi-Med received notification on 13 April 2015 that Simon To, Executive Director and Chairman, has purchased 25,000 ordinary shares of US$1.00 each in
Chi-Med (the "Shares") at a price of GBP14.215 per share on 10 April 2015.



Following this purchase, Mr To is beneficially interested in 152,000 Shares, representing approximately 0.29% of the current issued share capital of Chi-Med.

Hutchison China MediTech Ltd (HCM:LSE) set a new 52-week high during Tuesday's trading session when it reached 1,605. Over this period, the share price is up 100.25%.

Director Deals - Hutchison China Meditech Ltd (HCM)
BFN
Simon To, Chairman, bought 28,000 shares in the company on the 15th April 2015 at a price of 1585.00p. The Director now holds 180,000 shares.

Story provided by StockMarketWire.com
Director deals data provided by www.directorsholdings.com

Hutchison China MediTech Ltd (HCM:LSE) set a new 52-week high during today's trading session when it reached 1,785. Over this period, the share price is up 120.63%.

Director Deals - (HCM)
BFN
Christopher Nash, Non Executive Director, bought 1,388 shares in the company on the 21st April 2015 at a price of 1800.00p. The Director now holds 31,930 shares.

Story provided by StockMarketWire.com
Director deals data provided by www.directorsholdings.com

Savolitinib preliminary Phase Ib data presented
RNS
RNS Number : 7558O
Hutchison China Meditech Limited
01 June 2015









Savolitinib (AZD6094) preliminary Phase Ib clinical data in lung cancer presented at the 2015 ASCO Annual Meeting




London: Monday, 1 June 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM), today announces that AstraZeneca AB (publ) ("AstraZeneca"), Hutchison MediPharma Limited's ("HMP") collaboration partner, presented preliminary data from the ongoing Phase Ib clinical trial of HMP's c-Met inhibitor savolitinib (AZD6094) combined with AstraZeneca's drug candidate AZD9291 in non-small cell lung cancer ("NSCLC").



AZD9291 is AstraZeneca's investigational inhibitor of the epidermal growth factor receptor (EGFR). Preliminary data on the activity of AZD9291 in patients with EGFR mutation positive NSCLC who had failed currently-approved EGFR tyrosine kinase inhibitors was presented at the American Society of Clinical Oncology (ASCO) meeting in June 2014. In mid-2014 AstraZeneca commenced the TATTON study, a multi-arm Phase Ib study of AZD9291 in combination with either savolitinib (AZD6094) (c-MET inhibitor), MEDI4736 (anti-PD-L1 mAb) or selumetinib (MEK1/2 inhibitor) in EGFR mutation positive NSCLC. For those patients who received AZD9291 and savolitinib, the primary objective of the TATTON study was to establish a safe and effective combination dose. All patients were screened for their T790M status (+/-) as well as some, if sufficient tissue samples were available, for their c-Met (+/-) status.



The following poster was presented at the American Society of Clinical Oncology annual meeting in Chicago on 30 May 2015.



Title:
Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.

Authors:
Oxnard G.R., et al.

Abstract:
#2509 - available at abstracts.asco.org/156/AbstView_156_148945.html

Session:
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics

Date & Time:
Saturday 30 May 8:00 AM-11:30 AM




A total of 12 patients were dosed with either 600mg or 800mg daily doses of savolitinib (AZD6094) in combination with 80mg (once daily) AZD9291. In terms of the primary aims of the study, the 600mg combination dose was well tolerated with toxicity profiles that allow for combination at doses previously demonstrated to be biologically active. Of the 11 evaluable patients in the study, 6 partial responses (confirmed and unconfirmed) have been observed to date. Responses to date include 4 of 7 patients with confirmed T790M negative status.



The presentation will be made available at http://chi-med.com/eng/irinfo/presentations.htm.



Christian Hogg, Chief Executive Officer of Chi-Med said: "Savolitinib is a highly selective c-Met inhibitor designed to eliminate the toxicities experienced by the first wave of c-Met inhibitors in their early development. We are now very pleased to see encouraging early efficacy data emerge in non-small cell lung cancer to add to the efficacy already reported in papillary renal cell carcinoma and colorectal cancer."



Ends

Invention patent granted for SXBXP
RNS
RNS Number : 2903T
Hutchison China Meditech Limited
17 July 2015







20-year invention patent granted on Chi-Med's best selling prescription drug





London: Friday, 17 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its prescription drug joint venture, has been granted an invention patent in China ("Invention Patent") covering the formulation for the best selling prescription drug of Chi-Med for the treatment of cardiovascular diseases, She Xiang Bao Xin pill ("SXBXP"), until 2029, twenty years from its original filing date.



SXBXP is the most important prescription drug product of SHPL with sales in 2014 of US$138.8 million (2013: US$123.6m). SXBXP represents 90% of current SHPL sales and has grown at a compound annual average growth rate of 29% per year since 2007. It underpins the commercial operation of SHPL of over 1,700 medical representatives and marketing staff who manage the distribution and sales of SXBXP in approximately 13,500 hospitals, covering over 80,000 physicians, in China.



SXBXP was first approved for use in cardiovascular diseases in 1983 and subsequently enjoyed 22 years of proprietary commercial protection under the then regulatory system in China. In 2005, SHPL was able to attain "Confidential State Secret Technology" status protection on SXBXP, as certified by China's Ministry of Science and Technology and State Secrecy Bureau which extended proprietary protection of SXBXP until late 2016. The above Invention Patent will extend proprietary protection of SXBXP through 2029.



Christian Hogg, Chief Executive Officer of Chi-Med said: "The grant of this new patent will allow for this important cardiovascular therapy, to maintain its proprietary position in China for many years to come. SXBXP is the cornerstone proprietary prescription drug in Chi-Med's Commercial Platform in China -- a platform that we intend to leverage to launch many of the novel oncology and immunology drug candidates that we are currently developing in China if and when they receive regulatory approval."





Ends

Shares - Drug developer and distributor Hutchinson China MediTech is likely to see earnings forecasts upgraded after extending the patient on its top selling drug by 13 years. The China focused company , will now fend off generic competition for cardiovascular disease drug SXBXP until at least 2029. It was due to lose exclusivity of the drug , which accounts for 90% of the company's sales next year. Broker Panmure Gordon was quick to lift its price target to £17.50 from £16.50 following the news and is reviewing its forecasts.